Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP10740493A	2016-10-25	LTS LOHMANN Therapie-Systeme AG	Patent maintained as amended
EP11157819A	2014-06-11	Ahrens, Gabriele	Patent maintained as amended
EP02782151A	2013-06-12	Acino Pharma AG	Revoked
EP02782151A	2013-06-11	Germann, Sandra	Revoked
EP02801042A	2012-09-14	Ahrens, Gabriele	Patent maintained as amended
EP02801042A	2012-09-11	LTS LOHMANN Therapie-Systeme AG	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9687454	November, 2018	FWD Entered	Indivior UK Limited	Dr. Reddy’s Laboratories S.A.
US9687454	November, 2018	Terminated-Denied	Indivior UK Limited	Dr. Reddy's Laboratories S.A.
US8603514	June, 2017	Terminated-Denied	MonoSol Rx, LLC	Dr. Reddy’s Laboratories, Inc.
US8603514	June, 2017	Terminated-Denied	MonoSol Rx, LLC	Par Pharmaceutical, Inc.
US8603514	November, 2016	Terminated-Adverse Judgment	MonoSol Rx, LLC	Mylan Technologies, Inc.
US8475832	May, 2016	Terminated-Denied	Indivior UK Limited	Dr. Reddy’s Laboratories, Inc.
US8603514	May, 2016	Terminated-Denied	MonoSol Rx, LLC	Dr. Reddy's Laboratories, Inc.
US8017150	May, 2016	Terminated-Denied	MonoSol Rx, LLC	Dr. Reddy’s Laboratories, Inc.
US8017150	December, 2015	Terminated-Denied	MONOSOL RX, LLC	Teva Parmaceuticals USA Inc.
US8603514	December, 2015	Terminated-Denied	MONOSOL RX LLC	Teva Pharmaceuticals USA Inc
US8475832	December, 2015	Terminated-Denied	Indivior UK Limited	Teva Pharmaceuticals USA, Inc.
US8475832	June, 2014	Terminated-Denied	RB Pharmaceuticals Limited	BioDelivery Sciences International, Inc.
US8475832	January, 2014	FWD Entered	RB Pharmaceuticals Limited	BioDelivery Sciences International, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855221	INDIVIOR INC	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions	Feb, 2022 (1 year, 7 months ago)
US9931305	INDIVIOR INC	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions	Feb, 2022 (1 year, 7 months ago)
US10285910	INDIVIOR INC	Sublingual and buccal film compositions	Oct, 2022 (11 months ago)
US8017150	INDIVIOR INC	Polyethylene oxide-based films and drug delivery systems made therefrom	Feb, 2023 (7 months ago)
US8603514	INDIVIOR INC	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions	Apr, 2024 (6 months from now)
US11135216	INDIVIOR INC	Sublingual and buccal film compositions	Aug, 2029 (5 years from now)
US9687454	INDIVIOR INC	Sublingual and buccal film compositions	Aug, 2029 (5 years from now)
US8475832	INDIVIOR INC	Sublingual and buccal film compositions	Mar, 2030 (6 years from now)

Suboxone is owned by Indivior Inc.

Suboxone contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.

Suboxone has a total of 8 drug patents out of which 4 drug patents have expired.

Expired drug patents of Suboxone are:

US9855221
US9931305
US10285910
US8017150

Suboxone was authorised for market use on 30 August, 2010.

Suboxone is available in film;buccal, sublingual dosage forms.

Suboxone can be used as treating opioid use disorder, treatment of opioid dependence/sublingual or buccal application, this drug is administered by sublingual route to humans for maintenance treatment of opioid dependence.

The generics of Suboxone are possible to be released after 26 March, 2030.

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 August, 2010

Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence

Dosage: FILM;BUCCAL, SUBLINGUAL

Strength	Submission Date	ANDA(s) Filed	Last patent expiry	180 day status
2 mg/0.5 mg* and 8 mg/2 mg	15 Oct, 2012	1	13 Feb, 2023	Extinguished
4 mg/1 mg	14 May, 2013	1	13 Feb, 2023	Extinguished
12 mg/3 mg	14 May, 2013	1	13 Feb, 2023	Extinguished

Strength	Dosage	Availability
EQ 2MG BASE;EQ 0.5MG BASE	FILM;BUCCAL, SUBLINGUAL	Prescription
EQ 4MG BASE;EQ 1MG BASE	FILM;BUCCAL, SUBLINGUAL	Prescription
EQ 8MG BASE;EQ 2MG BASE	FILM;BUCCAL, SUBLINGUAL	Prescription
EQ 12MG BASE;EQ 3MG BASE	FILM;BUCCAL, SUBLINGUAL	Prescription

SUBOXONE family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Pharsight

Suboxone patents expiration

SUBOXONE family patents

Related content